Deputy Commissioner Anna K. Abram sent out the notice through the Federal Register acknowledging the following: “CBD has been shown to be beneficial in experimental models of several neurological disorders, including those of seizure and epilepsy.” (If you are a TheraJoy user, then I bet you already knew that; If you aren’t, you should be.)
The FDA would also like you to submit your first had CBD experiences that demonstrate it has viable medical benefits through their comment system.
FDA Deputy Commissioner admits CBD is beneficial in some cases
Recognizing the amazing benefits of CBD of cannabidiol early has been key to the success of TheraJoy; it gave us the time we needed to develop the perfect organic CBD oil and salve, and word of mouth did the rest. That being said, it feels amazing and maybe even a little vindicating to see key industry players such as the FDA Deputy Commissioner Anna K. Abram come to the same resolution, even if she is only willing to indirectly admit it.
Deputy Commissioner Anna K. Abram sent out the notice acknowledging the following: “CBD has been shown to be beneficial in experimental models of several neurological disorders, including those of seizure and epilepsy.”
In addition, The United Nations is trying to figure out how to categorize cannabidiol (CBD), a non-psychoactive and medically beneficial cannabinoid contained in cannabis. It was UN officials, through the US Food and Drug Administration (FDA), that initiated the request for public involvement.
Before I jump into the story, I feel it’s important to provide you with some context. Let’s start with CBD …
CBD is one of more than 80 active cannabinoid chemicals in the Cannabis plant. CBD, unlike THC, does not produce euphoria or intoxication. CBDs have their effect mainly by interacting with specific receptors on cells in the brain and body that regulate many other processes within our central and peripheral nervous systems.
… and the 1971 Convention on Psychotropic Substances …
The Convention on Psychotropic Substances of 1971 is a United Nations treaty designed to control psychoactive drugssuch as amphetamine-type stimulants, barbiturates, benzodiazepines, and psychedelics signed in Vienna, Austria on 21 February 1971.
As of 2013, 183 member states are Parties to the treaty. Many laws have been passed to implement the Convention, including the U.S. Psychotropic Substances Act, the UK Misuse of Drugs Act 1971, and the Canadian Controlled Drugs and Substances Act.
with that cleared up.
I said she indirectly admitted it, because Deputy Commission Abram made her indirect admission through a call for comments in the Federal Register (I just said Federal Register, don’t try to search for this on FDA.gov, you won’t find it. Here is the link.)
Here is the exact blurb where she makes the admission:
Cannabidiol (CBD) is one of the active cannabinoids identified in cannabis. CBD has been shown to be beneficial in experimental models of several neurological disorders, including those of seizure and epilepsy.
International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; Ocfentanil, Carfentanil, Pregabalin, Tramadol, Cannabidiol, Ketamine, and Eleven Other Substances; Request for Comments
Let me emphasize that statement, “CBD has been shown to be beneficial in experimental models of several neurological disorders, including those of seizure and epilepsy.” Those are her words folks, not mine.
As reported by Leafly, the FDA wants real CBD users, just like you, our loyal TheraJoy users, to submit comments on their experience using CBD as a healing substance.
FDA officials put out a call for comments in this morning’s Federal Register, seeking information about CBD and how the UN’s World Health Organization (WHO) should designate it under the 1971 Convention on Psychotropic Substances. In doing so, the FDA acknowledged the ‘beneficial’ effects CBD has shown in patients with neurological disorders.
All those who have information on, or experience with, the use of CBD as a healing substance are encouraged to comment at this federal website. Sept. 13 is the deadline for public comment, and no input will be considered after that date.
If CBD has provided you with a real medical benefit (I’m now speaking with all of our loyal TheraJoy users), then consider submitting your story in the form of a comment. Seriously consider it, because you could help change the industry for the better. You can comment here. Comments will be accepted until September 13th, 2017.
If you are unsure of exactly how to comment, then you may be interested in reviewing Regulations.gov “Tips for Submitting Effective Comments.” You can alternatively mail your comment in, but who uses snail mail these days.
One last thought, it is important to note that this process is different then federal legalization; Leafly sums it up.
CBD is one of 17 substances currently under scheduling review by the WHO. This process affects only the WHO and the United Nations. It does not directly deal with the status of CBD under the federal Controlled Substances Act—but it could have an indirect effect by influencing the outcome of the conflict over the federal categorization of cannabidiol.
While the impact on federal legalization is indirect at best, Deputy Commissioner Anna K. Abram’s admission is a great indicator that the government is not only willing to recognize the real medical benefits of CBD, they are actually starting to do it.
About FDA Deputy Commissioner Anna Abraham
As Deputy Commissioner for Policy, Planning, Legislation and Analysis, Anna Abram plays a critical role in overseeing the development and implementation of key policy initiatives and provides strategic policy direction to advance FDA’s mission and vision of protecting and promoting public health.
Prior to being appointed to this senior leadership position at the FDA, Ms. Abram served in the Office of the Secretary at the Department of Health and Human Services (HHS).